Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974023 | 0.95 | CYP19A1 (0.36) | CYP19A1CYP17A1CHRNB4CHRNA3HTT | |
| SCHEMBL4863042 | 0.88 | KMT2A (0.33) | CHRNB4CHRNA3HTTCHRNB2CHRNA4 | |
| SCHEMBL4862769 | 0.87 | MMP1 (0.33) | CHRNB2CHRNA4MMP1MMP2ADAM17 | |
| SCHEMBL4864094 | 0.85 | KCNA5 (0.38) | CYP19A1CYP17A1CHRNB4CHRNA3HTT | |
| SCHEMBL1975867 | 0.83 | KMT2A (0.36) | CYP19A1CHRNB4CHRNA3HTTCHRNB2 | |
| Hydrochloric Acid SCHEMBL4858247 | 0.82 | KMT2A (0.35) | CYP19A1CHRNB4CHRNA3HTTCHRNB2 | |
| SCHEMBL1972019 | 0.81 | CHRNB2 (0.35) | CHRNB2CHRNA4EPHX2 | |
| SCHEMBL1976002 | 0.81 | CHRNB2 (0.35) | CHRNB2CHRNA4EPHX2 | |
| SCHEMBL1974993 | 0.80 | KCNA5 (0.36) | CYP19A1CYP17A1CHRNB4CHRNA3CHRNB2 | |
| SCHEMBL1975703 | 0.78 | CCNC (0.37) | MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470671-B2 | Thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therapeutics | LABORATOIRE FOURNIER (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | LABORATOIRES FOURNIER S.A. (FR) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054955-A1 | Novel thioxylose compounds, preparation method thereof, pharmaceutical compositions containing same and use thereof in therepeutics. | NOTUM, STS, AGPS | CYP19A1 1066/4885CYP17A1 375/4885CHRNB4 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.